Pamiparib Granted Priority Review in China for Treatment of Advanced Ovarian Cancer

Pamiparib Granted Priority Review in China for Treatment of Advanced Ovarian Cancer
China's regulatory agency has granted priority review status to BeiGene's new drug application (NDA) requesting the approval of pamiparib, its investigational PARP inhibitor, for the treatment of advanced ovarian cancers. Priority review is granted in China to reduce the time to review and approve promising therapies that address urgent clinical needs. The NDA specifically covers patients with advanced ovarianfallopian tube, or primary peritoneal cancer who have been treated with two or more lines of chemotherapy and carry mutations in the BRCA genes. The priority review status comes days after the Center for Drug Evaluation of China's National Medical Products Administration agreed to review the application. “Pamiparib is our third internally developed drug candidate that has been granted priority review in China, following tislelizumab and
Subscribe or to access all post and page content.